Credit Suisse Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $550
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Dan Leonard has maintained an 'Outperform' rating on Bio-Rad Laboratories (NYSE:BIO) but lowered the price target from $580 to $550.

August 04, 2023 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Rad Laboratories' price target has been lowered by Credit Suisse from $580 to $550, though the 'Outperform' rating is maintained.
The lowering of the price target by Credit Suisse could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100